CoChat

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

Open access
Burmester, Gerd R, Weinblatt, Michael E, McInnes, Iain B, Porter, Duncan, Barbarash, Olga, Vatutin, Mykola, Szombati, Istvan, Esfandiari, Ehsanollah, Sleeman, Matthew A, Kane, Christopher D, Cavet, Guy, Wang, Bing, Godwood, Alex, Magrini, Fabio · 2013 · Annals of the Rheumatic Diseases
Cited by 157

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Mavrilimumab, a human monoclonal antibody targeting the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor, was evaluated in a phase 2 randomised, double-blind, placebo-controlled study to investigate efficacy and safety in subjects with rheumatoid arthritis (RA). METHODS: Subcutaneous mavrilimumab (10 mg, 30 mg, 50 mg, or 100 mg) or placebo was administered every other week for 12 weeks in subjects on stable background methotrexate therapy. The primary endpoint was the proportion of subjects achieving a ≥1.2 decrease from baseline in Disease Activity Score (DAS28-CRP) at week 12. RESULTS: 55.7% of mavrilimumab-treated subjects met the primary endpoint versus 34.7% placebo (p=0.003) at week 12; for the 10 mg, 30 mg, 50 mg, and 100 mg groups, responses were 41.0% (p=0.543), 61.0% (p=0.011), 53.8% (p=0.071), and 66.7% (p=0.001) respectively. Response rate differences from placebo were observed at week 2 and increased throughout the treatment period. The 100 mg dose demonstrated a significant effect versus placebo on DAS28-CRP<2.6 (23.1% vs 6.7%, p=0.016), all categories of the American College of Rheumatology (ACR) criteria (ACR20: 69.2% vs 40.0%, p=0.005; ACR50: 30.8% vs 12.0%, p=0.021; ACR70: 17.9% vs 4.0%, p=0.030), and the Health Assessment Questionnaire Disability Index (-0.48 vs -0.25, p=0.005). A biomarker-based disease activity score showed a dose-dependent decrease at week 12, indicating suppression of disease-related biological pathways. Adverse events were generally mild or moderate in intensity. No significant hypersensitivity reactions, serious or opportunistic infections, or changes in pulmonary parameters were observed. CONCLUSIONS: Mavrilimumab induced rapid clinically significant responses in RA subjects, suggesting that inhibiting the mononuclear phagocyte pathway may provide a novel therapeutic approach for RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2012-202450

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 157

Metadata

Authors
Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D., Barbarash, O., Vatutin, M., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D., Cavet, G., Wang, B., Godwood, A., & Magrini, F.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2013-09
Volume
72
Issue
9
Pages
1445-1452
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2147975139
Cited by
157
References
4
FWCI
12.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2012-202450
The paper
Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D., Barbarash, O., Vatutin, M., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D., Cavet, G., Wang, B., Godwood, A., & Magrini, F. (2013). Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-202450

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.